Last reviewed · How we verify

NCT06076798

Clinical Performance of AFGen1

Completed Last updated 11 April 2024
What this trial tests

trial testing ECG co-measurement in Atrial Fibrillation in 15 participants. Completed in 24 November 2023.

Timeline
5 October 2023
Primary endpoint
5 November 2023
24 November 2023

Quick facts

Lead sponsorTriVirum, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment15
Start date5 October 2023
Primary completion5 November 2023
Estimated completion24 November 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

TriVirum, Inc.

Who can join

Adults 18 to 90, any sex, with Atrial Fibrillation or Afib. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of AFGen1 on human participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ECG co-measurement

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other TriVirum, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06076798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing